apyrase has been researched along with Vasculitis* in 3 studies
2 review(s) available for apyrase and Vasculitis
Article | Year |
---|---|
CD39: Interface between vascular thrombosis and inflammation.
Extracellular nucleotides play a critical role in vascular thrombosis and inflammation. Alterations in purinergic extracellular nucleotide concentrations activate pathways that result in platelet degranulation and aggregation, and endothelial and leukocyte activation and recruitment. CD39, the dominant vascular nucleotidase, hydrolyzes ATP and ADP to provide the substrate for generation of the anti-inflammatory and antithrombotic mediator adenosine. The purinergic signaling system, with CD39 at its center, plays an important role in modulating vascular homeostasis and the response to vascular injury, as seen in clinically relevant diseases such as stroke, ischemia-reperfusion injury, and pulmonary hypertension. A growing body of knowledge of the purinergic signaling pathway implicates CD39 as a critical modulator of vascular thrombosis and inflammation. Therapeutic strategies targeting CD39 offer promising opportunities in the management of vascular thromboinflammatory diseases. Topics: Antigens, CD; Apyrase; Atherosclerosis; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Inflammation; Myocardial Ischemia; Myocardial Reperfusion Injury; Signal Transduction; Stroke; Thrombosis; Vasculitis | 2014 |
Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.
Transplantation results in exposure of the graft vasculature to warm and cold ischemia, followed by perfusion by circulating blood constituents and obligatory oxidant stress. Further graft injury occurs as consequences of acute humoral cellular rejection or chronic transplant vasculopathy, or both. Extracellular nucleotide stimulation of purinergic type 2 (P2) receptors are key components of platelet, endothelial cell (EC), and leukocyte activation resulting in vascular thrombosis and inflammation in vivo. CD39, the prototype nucleoside triphosphate diphosphohydrolase (NTPDase-1) is highly expressed on endothelium; in contrast, CD39L1/NTPDase-2 (a preferential adenosine triphosphatase [ATPase]) is found on vascular adventitial cells. Both ectoenzymes influence thrombogenesis by the regulated hydrolysis of extracellular nucleotides that differentially regulate P2-receptor activity and function in platelets and vascular cells. The intracytoplasmic domains of NTPDase-1 may also independently influence cellular activation and proliferation. NTPDase activity is substantively lost in the vasculature of injured or rejected grafts. A role for NTPDase-1 in thromboregulation has been validated by generation of mutant mice either null for cd39 or overexpressing human CD39. Administration of soluble NTPDase or induction of CD39 by adenoviral vectors, or both, are also of benefit in several models of transplantation. Administration of soluble CD39 or targeted expression may have future therapeutic application in transplantation-associated and other vascular diseases. Topics: Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Genetic Therapy; Graft Rejection; Humans; Ischemia; Mice; Mice, Inbred Strains; Mice, Knockout; Postoperative Complications; Rabbits; Rats; Rats, Inbred Lew; Receptors, Purinergic P2; Reperfusion Injury; Swine; Swine, Miniature; Thrombosis; Tissue and Organ Harvesting; Transplantation; Transplantation, Heterologous; Transplantation, Homologous; Vasculitis | 2005 |
1 other study(ies) available for apyrase and Vasculitis
Article | Year |
---|---|
Tuning the Thromboinflammatory Response to Venous Flow Interruption by the Ectonucleotidase CD39.
Objective- Leukocyte flux contributes to thrombus formation in deep veins under pathological conditions, but mechanisms that inhibit venous thrombosis are incompletely understood. Ectonucleotide di(tri)phosphohydrolase 1 ( ENTPD1 or Cd39), an ectoenzyme that catabolizes extracellular adenine nucleotides, is embedded on the surface of endothelial cells and leukocytes. We hypothesized that under venous stasis conditions, CD39 regulates inflammation at the vein:blood interface in a murine model of deep vein thrombosis. Approach and Results- CD39-null mice developed significantly larger venous thrombi under venous stasis, with more leukocyte recruitment compared with wild-type mice. Gene expression profiling of wild-type and Cd39-null mice revealed 76 differentially expressed inflammatory genes that were significantly upregulated in Cd39-deleted mice after venous thrombosis, and validation experiments confirmed high expression of several key inflammatory mediators. P-selectin, known to have proximal involvement in venous inflammatory and thrombotic events, was upregulated in Cd39-null mice. Inferior vena caval ligation resulted in thrombosis and a corresponding increase in both P-selectin and VWF (von Willebrand Factor) levels which were strikingly higher in mice lacking the Cd39 gene. These mice also manifest an increase in circulating platelet-leukocyte heteroaggregates suggesting heterotypic crosstalk between coagulation and inflammatory systems, which is amplified in the absence of CD39. Conclusions- These data suggest that CD39 mitigates the venous thromboinflammatory response to flow interruption. Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Blood Platelets; Cell Adhesion; Chemotaxis, Leukocyte; Gene Expression Regulation; Gene Regulatory Networks; Hemorheology; Ligation; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Receptors, Purinergic P2Y1; Vasculitis; Vena Cava, Inferior; Venous Thrombosis; von Willebrand Factor | 2019 |